37 results about "Uridine monophosphate" patented technology

The invention provides a method of preparing a phosphate. The method comprises the following step: enabling a pyrophosphate active compound expressed by formula II to react with uridine monophosphate expressed by a formula III or a salt thereof in a hydrophilic solvent under the action of a bimetallic ion composite catalyst to obtain P1,P4-bis (5'-uridine group) tetraphosphate expressed by formula I. In the formula II, X is imidazolyl, N-methyl imidazolyl, or 1, 2, 4-triazolyl; and the bimetallic ions in the bimetallic ion composite catalyst are a combination of any two of Zn2+, Mn2+, Mg2+, Fe2+, Fe3+ and Al3+. The method of preparing a phosphate employs a bimetallic catalytic system and can achieve high-efficiency and easy separation preparation of diquafosol.

The invention discloses a quality control method for ribonucleic acid II for injection. The method comprises the following steps that the nucleic acid enzyme hydrolysis solution of a substance to be measured is subjected to high-performance liquid chromatogram analysis, an adopted chromatographic column is an Agilent ZORBAX SB-AQC18 chromatographic column, and a flowing phase is a mixture of a formic acid solution and an acetonitrile solution; after the analysis, if the substance to be measured is determined to contain five substances as follows: cytidylate, uridine monophosphate, guanine nucleotide, guanosine and adenosine, the substance to be measured is the ribonucleic acid II for injection or is the ribonucleic acid II for injection as a candidate; and if not, the substance to be measured is not the ribonucleic acid II for injection or is not the ribonucleic acid II for injection as the candidate. A high-performance liquid chromatographic technique is utilized, and the strong-specificity quality control method for the ribonucleic acid II for injection is established. The method has important meanings on increasing the technological content of the medicine, increasing the safety and effectiveness, reducing the cost, enlarging the production scale, increasing the market occupancy, and going forward to the international market.

The invention discloses a screening method and an application of uridine monophosphate modified protein in mitochondria. The method is characterized in that biotin-labeled UTP (Biotin-16-UTP) is usedas a raw material, under the action of uridine monophosphate transferase SelO, total mitochondrial protein is subjected to UMP modification reaction, and the protein modified by UMP further has a biotin label, subsequently, the modified protein is screened out by using a biotin-streptavidin Pull-down technology, and finally, the modified protein and a modification site are determined by mass spectrometry. The method is advantaged in that a simple and feasible experimental method is developed, proteins which can be modified by UMP are screened from mitochondrial total proteins, and an importantresearch means is provided for signal transduction mediated by SelO proteins and post-translational modification in mitochondria.

This invention pertains to the use of an uridine source, preferably uridine monophosphate, for increasing, controlling and / or maintaining fasting plasma uridine concentrations in a range of 4 to 8 μM in a subject in need thereof, comprising administering to said subject a composition comprising 300-900 mg of said uridine source daily for a period of at least 4 weeks. In particular, the use of an uridine source is intended forelderly and / or subjects suffering from neurological disorders such as Alzheimer's Disease and dementia syndromes.

The invention discloses a preparing method of uridine diphosphite, which comprises the following steps: blending uridine monophosphate and beer yeast to ferment; terminating fermenting to obtain the ferment liquid of uridine triphosphate; predisposing ferment liquid; separating and purifying; proceeding acid heat to decompose purified uridine triphosphate; filtering; separating; refining. The invention shortens the predisposing time by two thirds and separating purifying time by one third, which makes receiving rate by over 30%.

The invention discloses a method for producing uridine diphosphate glucose and special engineering bacteria thereof. The invention provides a method for producing uridine diphosphate glucose, comprising the following steps: using uridine monophosphate and sucrose as raw materials, and under the action of engineering bacteria, producing uridine diphosphate glucose; The protein recombinant bacterium is obtained by introducing the gene encoding the functional protein into the starting bacterium, and the functional protein includes polyphosphate kinase, uridine monophosphate kinase and sucrose synthase. The invention has great significance for the industrialized production of uridine diphosphate glucose.

The present invention provides methods for increasing secretion of dopamine and other neurotransmitters and treating or reducing the incidence of diseases involving decreased secretion of dopamine and other neurotransmitters, e.g. Parkinson's disease, comprising administering to the subject a uridine or a source thereof, and compositions for treating or reducing an incidence of Parkinson's disease, comprising a uridine, a uridine monophosphate, or a source thereof.

The invention discloses a reagent box of screening the carrier of missing uridine monophosphate ribozyme of ox. The reagent box comprises a PCR primer pair and an endonuclease AvaI. The PCR primer pair comprises a primer pair comprising a deoxyribonucleotide with the sequence 1 in the sequence table and a deoxyribonucleotide with the sequence 2 in the sequence table. In the detection method of DUMPS heterozygote on herb based on genome DNA, the PCR-RFLP method is utilized to directly classify the genotype of Holstein cow, the method is not affected by animal age, sex and gene expression time, no radioactivity is used, no collection of comparison sample is required, and not only the determination work is reduced, but also the determination accuracy is promoted. Using the method to screen the carrier of missing uridine monophosphate ribozyme does not need special instrument and is favorable for the requirement of the conventional laboratory detection.

The invention discloses a preparation method of phosphate ester, and relates to the technical field of pharmaceutical chemicals. Uridine monophosphate or salt thereof and a pyrophosphoric acid activecompound are used, and under the action of a metal ion catalyst Ca<2+>, Mn<2+> or Mg<2+>, high-purity U2P4 can be obtained with high yield in large-scale industrial production.

The present invention relates to P 1 , P 4 The preparation method of two (uridine 5'-) tetraphosphates, the method comprises the following steps: imidazole triethylamine pyrophosphate shown in formula I and uridine monophosphate triethylamine salt shown in formula II, on metal Under the effect of salt catalyst, react in N,N-dimethylformamide, obtain the P shown in formula III 1 , P 4 Bis(uridine 5’-)tetraphosphate

The invention discloses a quality control method for ribonucleic acid II for injection. The method comprises the following steps that the nucleic acid enzyme hydrolysis solution of a substance to be measured is subjected to high-performance liquid chromatogram analysis, an adopted chromatographic column is an Agilent ZORBAX SB-AQC18 chromatographic column, and a flowing phase is a mixture of a formic acid solution and an acetonitrile solution; after the analysis, if the substance to be measured is determined to contain five substances as follows: cytidylate, uridine monophosphate, guanine nucleotide, guanosine and adenosine, the substance to be measured is the ribonucleic acid II for injection or is the ribonucleic acid II for injection as a candidate; and if not, the substance to be measured is not the ribonucleic acid II for injection or is not the ribonucleic acid II for injection as the candidate. A high-performance liquid chromatographic technique is utilized, and the strong-specificity quality control method for the ribonucleic acid II for injection is established. The method has important meanings on increasing the technological content of the medicine, increasing the safety and effectiveness, reducing the cost, enlarging the production scale, increasing the market occupancy, and going forward to the international market.

Medical dairy products are highly concentrated in proteins and minerals. Formulation of such products is challenging, since viscosities can easily increase during processing and storage. It was found that using one or more chelating agents selected from the group consisting of a phosphoric acid, citric acid, a soluble phosphate salt, a soluble citrate salt, or a mixture thereof, the viscosity and the transparency of an aqueous micellar casein composition, comprising 6 to 20 g / 100 ml of micellar casein and having a pH of about 6 to 8 could be controlled independently of each other. It was found that products become more viscous after addition of phytate, citrate, or orthophosphate, and that the viscosity depends on concentration and type of phosphate. Addition of hexametaphosphate leads to gel formation. In contrast, high concentrations of uridine monophosphate can be added without significantly affecting the viscosity.

The invention discloses a primer composition for detecting a harmful gene of deficiency of uridine monophosphate synthase of cattle, a kit with the primer composition and an application of the kit. The primer composition disclosed by the invention is composed of a primer group A and a primer group B, wherein the primer group A is composed of a primer 1 and a primer 2, the primer group B is composed of a primer 3 and a primer 4, and the nucleotide sequences of the primer 1, the primer 2, the primer 3 and the primer 4 are respectively shown as SEQIDNO. 1-4. The invention also provides the kit with the primer composition. The method for applying the kit disclosed by the invention to the detection of the harmful gene of the deficiency of uridine monophosphate synthase of cattle comprises the steps of extracting the complete set of DNA (Deoxyribonucleic acid) in cattle blood as a template to carry out nested PCR (Polymerase Chain Reaction) amplification to obtain a PCR product, and sequencing the obtained PCR product so as to directly know about the basic group change on a mutation site according to a sequenced result, thereby ensuring the accuracy of the result and meeting the requirements of a detecting technology for characteristics such as high speed, precision, high throughput and the like.